Ocera Therapeutics

Biopharmaceutical company developing novel therapeutics for patients with acute and chronic liver diseases.

Launch date

2005

Market cap

Enterprise valuation

CAD57m (Public information from Nov 2017)

Palo Alto California (HQ)

Date	Investors	Amount	Round
-	Redmont Capital	N/A	-
Jul 2006	Thomas McNerney & Partners Domain Associates Sofinnova Ventures	$12.0m	Series B
Feb 2008	Thomas McNerney & Partners Greenspring Associates FinTech Innovation Lab Domain Associates CDIB BioScience Ventures GeneChem Wasatch Advisors Cross Creek	$35.5m	Series C
Apr 2011	N/A	N/A	IPO
Mar 2012	N/A	$1.5m	Debt
Nov 2013	Venrock InterWest Partners Deerfield Partners Great Point Partners Three Arch Partners Vivo Capital RA Capital Management	$28.0m	Post IPO Equity
Aug 2015	Silicon Valley Bank Greenspring Associates Oxford Finance	$20.0m	Post IPO Debt
Nov 2017	Mallinckrodt	$42.0m Valuation: $42.0m	Acquisition
Total Funding		CAD64.8m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about Ocera Therapeutics